Myelodysplastic syndromes - Incidence and survival in the United States
Myelodysplastic syndromes - Incidence and survival in the United States
复制标题
DOI：
10.1002/cncr.22570
复制
发表时间：
2007-04-15
期刊：
影响因子：
6.2
通讯作者：
Mayne, Susan T.
中科院分区：
文献类型：
--
作者：
Ma, Xiaomei;Does, Monique;Mayne, Susan T.
背景2001年，骨髓增生异常综合征（MDS）开始向监测、流行病学和最终结果（SEER）计划（美国癌症监测计划）报告。这提供了第一次机会，检查在美国的MDS患者的发病率和生存率使用一个大型的，人口为基础的数据库。访问SEER 17个地区的公共使用数据库（2005年11月提交），以获得MDS患者的频率、发病率和生存率数据。选择纳入SEER计划的地理区域是基于其操作和维护高质量、基于人群的癌症报告系统的能力及其流行病学显著人群亚组。从2001年到2003年的SEER数据表明MDS的风险随着年龄的增长而增加，大约86%的MDS病例被诊断为年龄≥ 60岁的个体（诊断时的中位年龄= 76岁）。男性的发病率明显高于女性（每年每10万人中有4.5人对2.7人）。在种族群体中，白色个体的发病率最高。2003年，美国诊断出约10，300例MDS事件病例。MDS患者的生存率很低，观察到的3年生存率仅为35%（在本报告发布时，5年生存数据不可用）。男性患者和年龄较大的患者的生存率明显较差。MDS的生存率也因临床亚型而异，难治性贫血患者的生存率比以前报道的要差。MDS的描述性流行病学资料的可用性，现在可以用来促进急需的研究MDS的病因和结果。目前的结果表明，在美国每年诊断出> 10，000例MDS事件病例，并且MDS患者的存活率很差。MDS描述性流行病学数据的可用性，现在可以用来促进急需的研究MDS的病因和结果。
BACKGROUND. Myelodysplastic syndromes (MDS) became reportable to the Surveillance, Epidemiology, and End Results (SEER) Program (the United States cancer surveillance program) in 2001. This provided the first opportunity to examine the incidence and survival of patients with MDS in the United States using a large, population-based database.METHODS. The SEER 17 regions public-use database (November 2005 submission) was accessed to obtain data on the frequency, incidence, and survival of patients with MDS. Geographic areas were selected for inclusion in the SEER Program based on their ability to operate and maintain a high-quality, population-based cancer reporting system and for their epidemiologically significant population subgroups.RESULTS. SEER data from 2001 through 2003 indicated that the risk of MDS increased with age, and approximately 86% of MDS cases were diagnosed in individuals aged >= 60 years (median age at diagnosis = 76 years). Men had a significantly higher incidence rate than women (4.5 vs 2.7 per 100,000 per year). Among racial groups, white individuals had the highest incidence rate. In 2003, approximately 10,300 incident cases of MDS were diagnosed in the United States. The survival of MDS patients was poor, with an observed 3-year survival rate of only 35% (5-year survival data were not available at the time of the current report). Male patients and patients who were diagnosed at an older age had significantly worse survival. MDS survival also varied by clinical subtype, and the survival of patients who had refractory anemia was somewhat worse than reported previously. The availability of descriptive epidemiologic data on MDS can be used now to facilitate much needed research on the etiology and outcome of MDS.CONCLUSIONS. The current results indicated that >10,000 incident cases of MDS are diagnosed annually in the United States, and the survival of patients with MDS is poor. The availability of descriptive epidemiologic data on MDS can be used now to facilitate much needed research on the etiology and outcomes of MDS.